Similar articles

• The current management of carcinoma of the prostate.

  Rodriguez R, Carter HB. Rodriguez R, et al. Adv Surg. 1999;33:181-97. Adv Surg. 1999. PMID: 10572567 Review. No abstract available.
• Re: Adverse Pathology and Undetectable Ultrasensitive Prostate-Specific Antigen after Radical Prostatectomy: Is Adjuvant Radiation Warranted?

  Taneja SS. Taneja SS. J Urol. 2015 Dec;194(6):1631-2. doi: 10.1016/j.juro.2015.09.013. Epub 2015 Sep 8. J Urol. 2015. PMID: 26582665 No abstract available.
• [Treatment of prostate cancer].

  Romics I. Romics I. Orv Hetil. 2010 Apr 4;151(14):580-3. doi: 10.1556/OH.2010.28810. Orv Hetil. 2010. PMID: 20332076 Hungarian. No abstract available.
• Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

  Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L. Ploussard G, et al. BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30. BJU Int. 2011. PMID: 20883488
• Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.

  Doggrell SA. Doggrell SA. Expert Rev Anticancer Ther. 2009 Sep;9(9):1211-8. doi: 10.1586/era.09.95. Expert Rev Anticancer Ther. 2009. PMID: 19761424 Review.